# Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

> **NCT07117435** · PHASE1 · RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 7 (estimated)

## Conditions studied

- Colorectal Liver Metastases
- First-line Treatment

## Interventions

- **DRUG:** paclitaxel cationic liposome for injection
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07117435
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-01
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117435, "Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07117435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*